Image Place holder

Mihaela Druta, MD


Specialty: Medical Oncology
Program: Sarcoma

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia.  She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center.  Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center. Dr. Druta's clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients.  Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.

Education & Training

Board Certification:

  • Internal Medicine
  • Internal Medicine

Fellowship:

  • H. Lee Moffitt Cancer Center - Hematology and Medical Oncology
  • MD Anderson Cancer Center - Sarcoma Medical Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of Medicine and Pharmacy Carol Davilla - MD
Participating Trials

CLINICAL TRIAL 18739
A Phase 1 Dose Escalation And Cohort Expansion Study Of ERY974, AN ANTI-GLYPICAN 3 (GPC3)/CD3 Bispecific Antibody, In Patients With Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: ERY974
Open

CLINICAL TRIAL 18119
A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Condition: Sarcoma
Intervention: G100; G305; LV305; cyclophosphamide; cytoxan (cyclophosphamide)
Open

CLINICAL TRIAL 18350
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
Condition: Sarcoma
Intervention: MESNA; NY-ESO-1c259T; Neupogen (filgrastim); cyclophosphamide; cytoxan (cyclophosphamide); filgrastim; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18613
Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Condition: Sarcoma
Intervention: Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); gemcitabine
Open

CLINICAL TRIAL 18503
STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Condition: Thoracic
Intervention: Entrectinib
Open

CLINICAL TRIAL 18821
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients with Potentially Resectable Soft Tissue Sarcoma Treated with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin Combination Therapy
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); Olaratumab; doxorubicin
Open

CLINICAL TRIAL 18938
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
Condition: Multiple
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; KITE-718; MESNA; Proleukin (Interleukin-2); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19003
A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone In Patients with Advanced Angiosarcoma (TAPPAS)
Condition: Sarcoma
Intervention: Pazopanib; TRC105
Open

CLINICAL TRIAL 18136
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
Condition: Sarcoma
Intervention: Pembrolizumab (Keytruda)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Pham V, Henderson-Jackson E, Doepker MP, Caracciolo JT, Gonzalez RJ, Druta M, Ding Y, Bui MM. Practical Issues for Retroperitoneal Sarcoma. Cancer Control. 2016 Jul;23(3):249-264. Pubmedid: 27556665.
  • Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul;112(1):103-106. Pubmedid: 26179670.
  • Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?. Geriatr Oncol. 2014 Jan;5(1):40-48. Pubmedid: 24484717. Pmcid: PMC4527303.